NFGCM
SPRY icon

Norman Fields Gottscho Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Norman Fields Gottscho Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$569K Buy
71,080
+31,230
+78% +$269K 0.17% 46
2026
Q1 		$320K Buy
+39,850
New +$382K 0.11% 56

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Norman Fields Gottscho Capital Management's SPRY Position: Q2 2026 in Review

Norman Fields Gottscho Capital Management increased its ARS Pharmaceuticals (SPRY) stake by 78% in Q2 2026, buying an estimated $269K and bringing the position to 71,080 shares worth $569K. The position accounts for 0.17% of the portfolio, ranked #46.

Norman Fields Gottscho Capital Management first reported a position in SPRY in Q1 2026 and has held it in 2 quarters since. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Norman Fields Gottscho Capital Management held 71,080 shares of ARS Pharmaceuticals worth $569K as of Q2 2026.
  • Norman Fields Gottscho Capital Management bought 31,230 ARS Pharmaceuticals shares in Q2 2026, an estimated $269K.
  • ARS Pharmaceuticals made up 0.17% of Norman Fields Gottscho Capital Management's portfolio in Q2 2026, its #46 holding.
  • Norman Fields Gottscho Capital Management first reported a position in ARS Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Norman Fields Gottscho Capital Management's 13F filing for Q2 2026, filed 8 Jul 2026.